FDA updates data on breast implant-associated anaplastic large cell lymphoma

Editor's Note

In a March 21 Safety Alert, the Food and Drug Administration (FDA) updated its data on breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) to reflect the World Health Organization designation of BIA-ALCL as a rare T-cell lymphoma that can develop following breast implants.

At this time the data suggest that BIA-ALCL occurs more frequently after implantation of implants with textured rather than smooth surfaces and in patients undergoing implant revision surgery for late onset, persistent seroma. 

Posted 03/21/2017] AUDIENCE: Plastic Surgery, Oncology, Patient ISSUE: FDA has updated its understanding of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) to reflect the agency's concurrence with the World Health Organization designation of BIA-ALCL as a rare T-cell lymphoma that can develop following breast implants.